Literature DB >> 29699757

Psychometric Properties of the Sexual Event Diary in a Sample of Dutch Women With Female Sexual Interest/Arousal Disorder.

Yvonne van Nes1, Jos Bloemers2, Rob Kessels1, Peter G M van der Heijden3, Kim van Rooij4, Jeroen Gerritsen4, Leonard DeRogatis5, Adriaan Tuiten1.   

Abstract

BACKGROUND: Efficacy of on-demand drugs for women with hypoactive sexual desire disorder or female sexual interest/arousal disorder (FSIAD) should be assessed using a validated instrument that assesses the discrete sexual events during which the on-demand drug is taken, because this type of assessment is more proximate to an on-demand drug's efficacy compared to instruments that assess sexual function over longer periods of time. AIM: The aim of this study was to assess the psychometric properties of the Dutch translation of the previously validated 11-item Sexual Event Diary (SED) for measuring sexual satisfaction and sexual functioning during discrete sexual events.
METHODS: Psychometric assessment was performed on data of 1,840 SEDs from 139 women with hypoactive sexual desire disorder/FSIAD, collected during a randomized clinical cross-over trial conducted in the Netherlands. OUTCOMES: Item scores of the SED at the event level, and at subject level, summarized item scores during the placebo run-in period (PRI) and active treatment period, and score changes from PRI to active treatment period.
RESULTS: Reliability and convergent validity were confirmed. All item scores showed the ability to discriminate between known groups. Larger mean score changes from PRI were observed in groups with known benefit from the medication, as compared to those with no benefit. Guyatt effect sizes ranged from 0.51-1.02, thereby demonstrating ability to detect change. CLINICAL TRANSLATION: The Dutch version of the SED is an excellent instrument for assessing female sexual functioning and sexual satisfaction during discrete sexual events and for assessing these concepts over longer periods of time.
CONCLUSIONS: Data were collected in a randomized, well-controlled trial. The large number of data points gave high statistical power, and the results confirmed previous findings. However, care is needed when generalizing the SED's validity to other areas of research, eg, recreational drug use and sexual risky behaviors, since the current validation study has not used such data. Consistent with the US-English version, the Dutch version of the SED is a reliable, valid, and responsive instrument, and suitable for use in evaluating effects of on-demand drugs in women with FSIAD. van Nes Y, Bloemers J, Kessels R, et al. Psychometric Properties of the Sexual Event Diary in a Sample of Dutch Women With Female Sexual Interest/Arousal Disorder. J Sex Med 2018;15:722-731.
Copyright © 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dutch; Female Sexual Interest/Arousal Disorder; Hypoactive Sexual Desire Disorder; Patient-Reported Outcome; Psychometric Properties; Satisfactory Sexual Event; Sexual Event Diary; Sexual Function

Mesh:

Year:  2018        PMID: 29699757     DOI: 10.1016/j.jsxm.2018.03.082

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  2 in total

1.  Genotype scores predict drug efficacy in subtypes of female sexual interest/arousal disorder: A double-blind, randomized, placebo-controlled cross-over trial.

Authors:  Adriaan Tuiten; Frits Michiels; Koen Be Böcker; Daniël Höhle; Jack van Honk; Robert Pj de Lange; Kim van Rooij; Rob Kessels; Jos Bloemers; Jeroen Gerritsen; Paddy Janssen; Leo de Leede; John-Jules Meyer; Walter Everaerd; Henderik W Frijlink; Hans Pf Koppeschaar; Berend Olivier; James G Pfaus
Journal:  Womens Health (Lond)       Date:  2018 Jan-Dec

2.  A multilevel structural equation model for assessing a drug effect on a patient-reported outcome measure in on-demand medication data.

Authors:  Rob Kessels; Mirjam Moerbeek; Jos Bloemers; Peter G M van der Heijden
Journal:  Biom J       Date:  2021-07-16       Impact factor: 1.715

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.